Effects of Endocrine Interventions Targeting ERα or PR on Breast Cancer Risk in the General Population and Carriers of

Deborah Huber, Maria Hatzipanagiotou, Susanne Schüler-Toprak, Olaf Ortmann, Oliver Treeck

Abstract readReview

In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Hormone Therapy After Oophorectomy and Breast Cancer Risk in Women With BRCA Pathogenic Variant.JAMA network open · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Deborah HuberDepartment of Gynecology and Obstetrics, University Medical Center Regensburg, 93053 Regensburg, Germany.ORCID 0000-0002-8741-4585

Maria HatzipanagiotouDepartment of Gynecology and Obstetrics, University Medical Center Regensburg, 93053 Regensburg, Germany.

Susanne Schüler-ToprakDepartment of Gynecology and Obstetrics, University Medical Center Regensburg, 93053 Regensburg, Germany.

Olaf OrtmannDepartment of Gynecology and Obstetrics, University Medical Center Regensburg, 93053 Regensburg, Germany.

Oliver TreeckDepartment of Gynecology and Obstetrics, University Medical Center Regensburg, 93053 Regensburg, Germany.ORCID 0000-0003-2353-9693

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is evidence suggesting that endocrine interventions such as hormone replacement therapy and hormonal contraception can increase breast cancer (BC) risk. Sexual steroid hormones like estrogens have long been known for their adverse effects on BC development and progression via binding to estrogen receptor (ER) α. Thus, in recent years, endocrine interventions that include estrogens have been discussed more and more critically, and their impact on different BC subgroups has increasingly gained interest. Carriers of pathogenic variants in

Indexed as

BRCA1 ProteinBRCA2 ProteinBreast NeoplasmsEstrogen Receptor alphaFemaleGenetic Predisposition to DiseaseHeterozygoteHumansMutationReceptors, ProgesteroneBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanESR1 protein, humanEstrogen Receptor alphaReceptors, ProgesteroneBRCA1/2 mutationbreast cancer riskestrogen metabolismhormonal contraceptionhormone replacement therapy

Identifiers

PMID38892081

DOI10.3390/ijms25115894

PMCPMC11172552

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.